RSPO1 and neoplasm: Chartier et al. generated monoclonal antibodies against RSPO1–3, and showed that these inhibited tumor growth (both as single agent or in combination with chemotherapy) in multiple PDX cancer models with overexpression of the respective RSPO [116].